CS Paper Radar

Disease-level drug approval forecasting from trial-agnostic public data

Samir Townsley, Pagkratios Tagkopoulos, Ilias Tagkopoulos

cs.LG q-bio.QM ·submitted 2026-09-29 06:23 UTC · v1

Abstract

Drug development is an expensive and lengthy process requiring developers to select drugs for human trials and diseases to target. Computational tools that can estimate before testing which drug-disease candidates are most likely to reach FDA approval could reduce development time and costs through early program advancement and disease prioritization. Yet existing approaches predict outcomes at a single level or stage or do not distinguish between disease outcomes for the same drug. We ask (1) whether FDA approval can be forecast for a drug-disease pair using only pre-clinical trial information, and (2) whether these forecasts can help prioritize diseases for the same drug. We built a cohort of 14,134 drug-disease pairs by reconstructing programs from ClinicalTrials.gov, extracting disease-level approvals from FDA label documentation, and enriching each pair with molecular, disease, ADMET, target, and pathway features. We divided the cohort into pre- and post-2019 programs and trained a classifier on pre-2019 data to predict FDA approval. On the post-2019 cohort (2,637 programs), the model would have prioritized a program that ultimately gained approval over one that did not approximately three out of four times. For drugs tested across multiple diseases, selecting the model's highest-ranked disease would have identified an ultimately approved disease 61.3% of the time, compared with 40.7% under random selection. These results show that public pre-trial information contains signal for forecasting FDA approval at the drug-disease level and can help prioritize diseases for the same drug. We provide a public web tool for SMILES- and ICD-10-based drug-disease approval forecasting.

Closest papers

Nearest neighbours by meaning across the whole index.

Pretrained Medical Representations for the Practical Screening of Drug Repositioning Candidates

cs.LG ·2026-09-17 ·Yuhei Fujioka, Daitaro Misawa, Shingo Fukuma
published similarity 0.68
Abstract · Accepted at ICML 2026 AI for Science Workshop

Representation learning from medical code sequences in electronic health records and medical claims data has been successful in various clinical applications, such as those regarding disease prediction. However, significant challenges remain in extending this approach to the discovery of scientific hypotheses. One reason is that many existing BERT-based models fail to adequately capture the hierarchical structure of medical codes and the complex interactions between diagnoses and treatments. To address these limitations, we propose a new unified pre-training framework that explicitly integrates hierarchical sub-token aggregation, partial masking, and cross-reference mechanisms. The proposed model consistently outperformed existing methods on both pre-training objectives and downstream clinical event prediction tasks, including the onset of dementia and hospitalization. We also conducted an in silico drug repositioning case study targeting Alzheimer's disease. In the hypothesis generation step, our approach successfully rediscovered known promising drugs in a data-driven manner without relying on such external knowledge sources as the literature. Subsequently, in the hypothesis prioritization step, we introduced a Task-Adaptive Representation Approach to alleviate the over-encoding of historical prescription information within diagnostic vectors, enabling the robust prioritization of generated hypotheses. This study establishes an exploratory screening workflow for hypothesis generation and prioritization based on observational associations. Importantly, this framework is not intended to provide causal evidence, but rather to identify promising candidates for subsequent rigorous causal inference. Overall, this study demonstrates that domain-informed representation learning combined with task-adaptive representation control can enable a practical hypothesis discovery workflow.

0.23

Advancing Clinical Trial Outcome Prediction with Domain-Specific Large Language Models

cs.AI ·2026-10-30 ·Burak Bakkar, Hana Moalla, Mohamed Salem Jedidi, Haifa Ben Messaoud, Nicolas Lopez Carranza
benchmark similarity 0.67
Abstract

Clinical trial failures are a major barrier to efficient drug development, incurring substantial costs and delaying patient access to effective therapies. Structured approaches such as the Hierarchical Interaction Network (HINT) predict trial outcomes by explicitly modelling interactions between drugs, diseases and protocols, but make limited use of the free text in trial registrations. We evaluate two domain-specific language models, BioBERT (108M parameters) and BioMistral (7B parameters), for phase-level outcome prediction on the TOP benchmark (12,477 trials), representing each trial as text built from ten ClinicalTrials.gov fields. We compare fine-tuning (full fine-tuning for BioBERT, low-rank adaptation for BioMistral) with probing, in which the pretrained model is frozen and only a lightweight classifier is trained on its embeddings. On the held-out test set of each phase, all four language-model variants achieved higher ROC-AUC (0.613--0.772) and PR-AUC (0.649--0.901) than the published HINT results, corresponding to relative PR-AUC gains of 10--20\%. F1 differences were small and mixed, and no model, including HINT, clearly exceeded the F1 of a trivial classifier that predicts success for every trial. Under the configurations tested, probing performed comparably to fine-tuning: fine-tuned models scored highest on ROC-AUC and PR-AUC in Phases I and II, and frozen BioMistral embeddings in Phase III (ROC-AUC 0.772; PR-AUC 0.901), although most differences between variants were below 0.03 and were not tested for significance. These results suggest that pretrained biomedical representations already encode signal relevant to trial outcome, and that probing is a computationally cheaper alternative to fine-tuning for this task.

0.22

Large-scale AI-Ready Data for Anti-Cancer Drug Response Modeling

cs.LG q-bio.QM ·2026-08-11 ·Vincent Lavelle, Yitan Zhu, Kaitlyn Marlor, Thomas Brettin, Rick Stevens
benchmarkdataset similarity 0.66
Abstract

Drug response prediction (DRP) models are an active area of research in pharmacogenomics, with growing potential to accelerate the identification of effective anticancer drugs. However, their predictive performance is often constrained by limited dataset scale and insufficient coverages of cancer and chemical spaces. In addition, inconsistent benchmarking practices hinder reliable comparison across models. Standardized frameworks, such as the Innovative Methodologies and New Data for Predictive Oncology Model Evaluation (IMPROVE) project, provide unified data schemas and evaluation protocols for consistent benchmarking, but improving model generalizability requires larger and more diverse training data. In this work, we substantially expand the IMPROVE benchmark through large-scale integration of pharmacogenomic data, primarily from PharmacoDB, together with additional smaller data sources. The expanded resource includes millions of drug response measurements, broader multi-omics coverage, and a major increase in chemical diversity, adding more than 50,000 compounds. To evaluate the impact of the new dataset compared to the original IMPROVE benchmark dataset, we trained DRP models using the two datasets and assess their prediction performance using a common test set and several evaluation strategies, including drug-blind, cancer-blind, and disjoint data splits. While cancer-blind performance remained comparable to the original benchmark, models trained on the expanded dataset showed consistent improvements in drug-blind and disjoint settings, indicating enhanced generalization to previously unseen compounds. These results position the expanded dataset as a community resource that provides a richer foundation for developing DRP models intended to aid in the discovery of novel anticancer drugs.

0.04

TrialAtlas: Multi-Agent Research Organization for Clinical Trial Design and Optimization

cs.CL ·2026-09-18 ·Jiacheng Lin, Zifeng Wang, Zheng Chen, Erick Scott, Ziwei Yang +3 more
similarity 0.66
Abstract

Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely on clinical development planning (CDP) and probability of technical and regulatory success assessment to anticipate development risks, yet these decisions remain labor-intensive and subjective, requiring experts across clinical science, statistics, regulatory affairs, and competitive intelligence to jointly acquire, synthesize, and reason over heterogeneous evidence. Here, we introduce TrialAtlas, a memory-augmented multi-agent research organization for CDP that mirrors this collaborative process by coordinating specialized agents for literature synthesis, competitive trial intelligence, regulatory precedent analysis, and integrated reasoning over trial design and development risk. TrialAtlas further learns from historical clinical trials and regulatory outcomes, including prior New Drug Applications (NDAs), to ground its decisions in accumulated development experience. To evaluate these capabilities in an authentic regulatory setting, we introduce TrialAtlasBench, constructed from 291 FDA Complete Response Letters and spanning three practical tasks: detecting trial design deficiencies, recommending actionable design improvements, and predicting technical and regulatory success. TrialAtlas achieves an F1 score of 50.0% for deficiency detection, outperforming the strongest baseline by 6.1 points, and reaches 85.3% balanced accuracy and 84.7% F1 for prediction of technical and regulatory success, improving over the best baselines by 6.7 points in balanced accuracy and 12.0 points in Cohen's kappa. In expert evaluation, 86.4% of TrialAtlas-generated concerns were judged valid, compared with 83.1% for OpenAI DeepResearch and 59.3% for Gemini DeepResearch.

0.40

ScreenShot: A Foundation Model for Few-Shot Combination Drug Screening

cs.LG ·2026-08-12 ·Antoine de Mathelin, Christopher Tosh, Wesley Tansey
code/data similarity 0.66
Abstract

Treating patients with combinations of drugs reduces the risk of resistance to any individual drug. Finding effective combinations is difficult because the large search space makes combinatorial screens prohibitively expensive, time consuming, and often technically infeasible. Predictive models can fill this gap, yet existing methods typically require molecular profiling of each sample and per-cohort training, limiting their applicability when time and tissue are scarce. To address this challenge, we introduce ScreenShot, a hierarchical transformer pretrained on 40 drug screening datasets covering 3,700 drugs and 6,000 biological samples, whose architecture mirrors the nested structure of screening data. Given a few-shot context of observations from a new patient, ScreenShot predicts the response of the sample to combination therapies through in-context learning, operating directly on functional measurements with no fine-tuning and no molecular profiling. On four held-out datasets, ScreenShot outperforms all baselines in both prediction accuracy and identification of selectively effective treatments. ScreenShot's internal representations are directly useful for experimental design: we use them to drive a weighted k-means++ active learning strategy that selects which experiments to run, achieving the same hit detection as uniform screening with a third of the budget. Source code and interactive dashboard: https://github.com/tansey-lab/screenshot.

0.24

PDO Drug Screening Data for Evaluating and Training AI Drug Response Prediction Models

cs.AI q-bio.QM ·2026-11-11 ·Y. Zhu, K. Marlor, V. Lavelle, T. S. Brettin, M. Sacco +4 more
code/data similarity 0.64
Abstract

Anti-cancer drug response prediction (DRP) is critically important for precision oncology and therapeutic development. Currently, most DRP models are developed using drug screening data from immortalized cancer cell lines, which can differ substantially from patient tumors at the genomic and molecular levels, even though patient tumor response is the ultimate prediction target. To help bridge this gap and bring DRP models closer to their intended clinical application, we conducted four drug screening studies using patient-derived organoids (PDOs), which more faithfully recapitulate patient tumors than immortalized cell lines. These studies generated data for improving and evaluating DRP models, including multi-omics profiles of PDO lines, drug feature data, and treatment response measurements. Using these data, we retrained and evaluated multiple publicly available DRP models under three model-building scenarios: training models using cell line data only, training models using combined cell line and PDO data, and pretraining models on cell line data followed by fine-tuning on PDO data. We then evaluated and compared model prediction performance on PDOs across these analysis scenarios. In addition, we also assessed the consistency of drug screening viability data generated by different laboratories using different assay technologies and/or experimental protocols.

0.45

Foundation Agents Meet Agentic Deep Research: Evidence-Grounded Clinical Code Forecasting

cs.CL cs.AI ·2026-08-17 ·Junda Wang, Meysam Ghaffari, Akshat Choube, Mohsen Sharifi Renani, Hong Yu +1 more
hot direction similarity 0.63
Abstract

Next-encounter ICD forecasting predicts which standardized diagnosis codes will be documented at a future visit from the longitudinal record available beforehand. The task is prospective and multi-label: the target note does not yet exist, and several codes may be correct. Structured EHR foundation models capture recurrence and temporal progression, whereas language foundation models generate flexible diagnostic hypotheses. We introduce ICD-Deepresearch, a DeepResearch workflow that composes these predictive foundation models with medical search and ICD dictionaries. Because no source reveals the future code set, research evaluates candidate transitions by linking patient evidence, external clinical relations, and exact code semantics under a fixed top-K budget. Candidate Generation uses SparseEHR to produce an EHR Prior that initializes two bounded Research Expansion rounds; an independent GPT-5 Direct Forecast supplies complementary candidates. Final Selection validates, deduplicates, and jointly ranks both paths, after which a separate module writes rationales without changing predictions. Finally ICD-Deepresearch achieves patient-averaged precision/recall of 24.60/35.09% on MIMIC-III and 25.14/48.32% on MIMIC-IV. Physicians rate 51% and 68% of its retrieved documents useful, compared with 22% and 39% for standalone GPT-5 web search and 32% and 41% for Medical Deep Research. ICD-Deepresearch therefore improves over the registered local comparators while retrieving evidence with higher physician-rated usefulness than the standalone research systems

0.27

ColdDDI: Evaluating Knowledge Utilization in Cold-Start Drug-Drug Interaction Prediction

cs.LG cs.CL ·2026-10-04 ·Jiheng Liang, Chen Zhao, Di Wu, Chenyang Bu, Yunpeng Hong +2 more
publishedbenchmarkcode/data similarity 0.63
Abstract · Accepted at NeurIPS 2026 (poster). Code: https://github.com/0217ljh/ColdDDI-NeurIPS2026

Cold-start drug-drug interaction (DDI) prediction tests whether models can identify clinically significant interactions for drugs without training-time interaction history. Existing benchmarks mostly report aggregate edge-prediction scores, leaving a key evaluation question unanswered: when models receive molecular, textual, or knowledge-graph (KG) evidence, do they actually use the evidence that pharmacologically supports the interaction? We introduce ColdDDI, a reconstructible diagnostic benchmark built from DrugBank 5.1.13, with 1,900 approved small-molecule drugs and 565,731 positive DDI pairs. ColdDDI evaluates pairs with zero, one, or two unseen drugs. It also annotates each interaction by whether it changes drug exposure or drug effect, and by whether the biomedical knowledge graph contains shared enzymes, transporters, or targets that can plausibly mediate the interaction. These annotations separate evidence availability from predictive dependence. We evaluate eight conventional DDI methods and 13 LLMs; for open-weight LLMs, we test five prompt patterns and use masking, drug replacement, and channel-sensitivity metrics to probe knowledge utilization. ColdDDI exposes that, in the hardest split where both drugs are unseen, the main performance divide is mediator availability. A fine-tuned 1B LLM recovers 89-93% of interactions with a shared enzyme, transporter, or target, but only 40-62% without such a mediator. More importantly, KG-provided evidence is not always used; several KG-augmented baselines change little when the shared mediator is masked or disrupted, whereas fine-tuned LLMs respond strongly to this intervention. Thus, ColdDDI evaluates knowledge utilization rather than knowledge access alone, showing where cold-start DDI models rely on mechanistic evidence and where they fail despite receiving it. Code is available at https://github.com/0217ljh/ColdDDI-NeurIPS2026.

0.39